Avidity Biosciences Company Insiders

RNA Stock  USD 30.84  0.01  0.03%   
Avidity Biosciences' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Avidity Biosciences suggests that vertually all insiders are panicking. Avidity Biosciences employs about 391 people. The company is managed by 18 executives with a total tenure of roughly 913 years, averaging almost 50.0 years of service per executive, having 21.72 employees per reported executive.

Insider Sentiment 0

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-02-03Kathleen P GallagherDisposed 5875 @ 32.16View
2025-01-21Michael F MacleanDisposed 3287 @ 28.59View
2024-12-18W. Michael FlanaganDisposed 12742 @ 32.66View
2024-12-16Teresa MccarthyDisposed 25000 @ 33.26View
2024-12-11W. Michael FlanaganDisposed 24000 @ 35.77View
2024-11-19Arthur A LevinDisposed 3323 @ 42.12View
2024-11-18Teresa MccarthyDisposed 25000 @ 41.14View
2024-10-21Arthur A LevinDisposed 5000 @ 46.63View
2024-10-16Teresa MccarthyDisposed 25000 @ 48.52View
2024-10-07Tamar ThompsonDisposed 30000 @ 44.98View
2024-09-23Michael F MacleanDisposed 11510 @ 44View
2024-09-19Arthur A LevinDisposed 5000 @ 45.73View
2024-08-19Arthur A LevinDisposed 5000 @ 45.19View
Monitoring Avidity Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Avidity Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.

Avidity Biosciences' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Avidity Biosciences' future performance. Based on our forecasts, it is anticipated that Avidity will maintain a workforce of about 390 employees by April 2025.
 
Covid

Avidity Biosciences Management Team Effectiveness

The company has Return on Asset of (0.2161) % which means that on every $100 spent on assets, it lost $0.2161. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3347) %, meaning that it generated no profit with money invested by stockholders. Avidity Biosciences' management efficiency ratios could be used to measure how well Avidity Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of March 22, 2025, Return On Tangible Assets is expected to decline to -0.22. The current year's Return On Capital Employed is expected to grow to -0.25. At present, Avidity Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 42.8 M, whereas Other Assets are forecasted to decline to 0.86.
As of March 22, 2025, Common Stock Shares Outstanding is expected to decline to about 56.3 M. The current year's Net Loss is expected to grow to about (148.8 M)

Avidity Biosciences Workforce Comparison

Avidity Biosciences is rated third in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 3,551. Avidity Biosciences retains roughly 391 in number of employees claiming about 11% of equities under Health Care industry.

Avidity Biosciences Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avidity Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avidity Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Avidity Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
0.8077
21
26
 924,250 
 169,656 
2024-12-01
0.4167
10
24
 278,880 
 586,739 
2024-09-01
0.8261
19
23
 675,000 
 504,937 
2024-06-01
0.931
27
29
 989,976 
 1,339,762 
2024-03-01
0.7778
14
18
 959,500 
 549,402 
2023-12-01
0.5
1
2
 250,000 
 550,000 
2023-03-01
1.2308
16
13
 1,160,600 
 140,200 
2022-12-01
0.5
1
2
 40,000 
 80,000 
2022-09-01
0.4545
5
11
 80,100 
 217,550 
2021-12-01
0.6667
2
3
 25,000 
 50,000 
2021-06-01
0.75
9
12
 95,400 
 293,822 
2021-03-01
2.2
11
5
 932,622 
 46,222 
2020-12-01
1.0
1
1
 100,000 
 100,000 
2020-06-01
0.36
9
25
 11,601,644 
 23,606,893 

Avidity Biosciences Notable Stakeholders

An Avidity Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Avidity Biosciences often face trade-offs trying to please all of them. Avidity Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Avidity Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Sarah BoyceCEO PresidentProfile
Geoffrey CFAVP CommunicationProfile
Kathleen GallagherChief OfficerProfile
Teresa McCarthyChief OfficerProfile
Eric MosbrookerChief OfficerProfile
III JDConsultantProfile
Michael CPAChief OfficerProfile
Michael MacLeanChief OfficerProfile
Prof DavisMember FounderProfile
Charles IIIChief OfficerProfile
MD MBAChief OfficerProfile
Moriarty ESQChief SecretaryProfile
Arthur LevinStrategic ScientistProfile
John IIIGeneral PropertyProfile
Troy JDCoFounder ChairmanProfile
Frank McCormickScientific BoardProfile
W FlanaganChief OfficerProfile
Michael FlanaganChief OfficerProfile

About Avidity Biosciences Management Performance

The success or failure of an entity such as Avidity Biosciences often depends on how effective the management is. Avidity Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Avidity management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Avidity management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.21)(0.22)
Return On Capital Employed(0.26)(0.25)
Return On Assets(0.21)(0.22)
Return On Equity(0.23)(0.21)
Please note, the presentation of Avidity Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Avidity Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Avidity Biosciences' management manipulating its earnings.

Avidity Biosciences Workforce Analysis

Traditionally, organizations such as Avidity Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Avidity Biosciences within its industry.

Avidity Biosciences Manpower Efficiency

Return on Avidity Biosciences Manpower

Revenue Per Employee27.9K
Revenue Per Executive605.4K
Net Loss Per Employee824.3K
Net Loss Per Executive17.9M
Working Capital Per Employee3.7M
Working Capital Per Executive80.2M

Complementary Tools for Avidity Stock analysis

When running Avidity Biosciences' price analysis, check to measure Avidity Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avidity Biosciences is operating at the current time. Most of Avidity Biosciences' value examination focuses on studying past and present price action to predict the probability of Avidity Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avidity Biosciences' price. Additionally, you may evaluate how the addition of Avidity Biosciences to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio